The goal is to replace the majority of the former incumbent HEXO board members and to redress the disappointing performance of the underperforming company. HEXO is a Canadian cannabis company focused on smoke-free and traditional cannabis products.
Severe Financial Distress
Arviv, who currently owns a roughly 2% stake in HEXO, has fought a battle with the cannabis company’s management over the past few months since the company’s August 2021 acquisition of licensed producer Redecan.
Arviv alleges that former Chairman of the Board, Dr. Michael Munzar, and former CEO, Sebastien St-Louis, deceived the Redecan investor group and destroyed shareholder value by carrying out a number of destructive financings and that the incumbent board, led by current chairman John Bell and director Vincent Chiara, was grossly negligent in approving these transactions.
HEXO’s Share Price Sinks Below a Dollar
As of the date of Arviv’s letter, HEXO common stock was trading at a 52-week low of C$0.58, down from a high of C$14, within one year.
The departure of Mr. St-Louis, which was effective immediately on October 18, 2021, was not enough to halt the steep decline in share value, with HEXO shares having fallen more than 50% since that day.
Arviv will submit the names of five independent candidates to replace the majority of the current members of the board at the next annual and special meeting of shareholders scheduled for March 8, 2022.
Wall Street’s Take
On January 28, Jefferies analyst Own Bennett upgraded HEXO to Hold from Sell and set a C$0.67 price target. This implies 20% downside potential.
The consensus among analysts is that HEXO is a Moderate Sell based on three Holds and two Sells.
The average HEXO price target of C$0.90 implies 8.5% upside potential to current levels.
TipRanks’ Smart Score Rating
HEXO scores a 1 out of 10 on TipRanks’ Smart Score rating system, indicating that the stock is likely to underperform the overall market.
Download the TipRanks mobile app now
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.